Table 2 Efficacy and severe adverse events in included studies
Author | Year | Treatment | Sample size (N) | CR + PR, N (%) | CR, N (%) | NR, N (%) | Relapse N (%) | SAE Patients, N (%) | Immunological response, N (%) | Funding (N) | RTX dose |
|---|---|---|---|---|---|---|---|---|---|---|---|
Medrano [18] | 2014 | RTX + TAC | 53 | 49 (92.5) | 28 (57) | 4 (7.5) | 0 (0) | NA | 77% at 12 months | None | RTX 1 g on days 1 and 15 or 4 weekly doses of 375 mg/m2 |
CYC + CS | 26 | 19 (73) | 6 (32) | 7 (27) | 0 (0) | NA | 58% at 12 months | ||||
van den Brand [15] | 2017 | RTX | 100 | 64 (64) | 26 (26) | NA | NA | 9 (9) | NA | 3a | RTX 4 weekly doses of 375 mg/ m2 |
CYC + CS | 103 | 89 (86.4) | 34 (33) | NA | NA | 30 (29.1) | NA | ||||
Fenoglio [17] | 2020 | RTX low | 14 | 13 (92.8) | 12 (85.7) | 1 (8) | 1 (8) | 1 (8) | 93% at 3–6 months | None | 1 dose of RTX 375 mg/m2 |
RTX standard | 14 | 13 (92.8) | 13 (92.8) | 1 (8) | 0 (0) | 2 (15) | 93% at 3–6 months | RTX 4 weekly doses of 375 mg/ m2 | |||
CYC + CS | 14 | 12 (85.7) | 12 (85.7) | 2 (17) | 1 (8) | 3 (25) | NA | ||||
Fernandez-Juarez | 2020 | RTX + TAC | 43 | 25 (58) | 11 (26) | NA | 3 (12) | 6 (14) | 45%, 70%, 79%, 83% at 3, 6, 12, and 18 months | 10 b | RTX 1 g |
[13] | CYC + CS | 43 | 36 (84) | 26 (60) | NA | 1 (2) | 8 (19) | 77%, 92%, 88%, 88% at 3, 6, 12, and 18 months | |||
Scolari [14] | 2021 | RTX | 37 | 17/20 (85) | 6/20 (30) | NA | 3 (13) | 7 (19) | 63%, 62%, and 91% at 6, 12, and 18 months | None | RTX 1 g on days 1 and 15 |
CYC + CS | 37 | 16/22 (73) | 7/22 (32) | NA | 6 (22) | 5 (14) | 50%, 56%, and 73% at 6, 12, and 18 months | ||||
Ramachandran [16] | 2021 | RTX | 13 | 5 (38.5) | NA | NA | NA | 5 (38.5) | NA | 2c | RTX 4 weekly doses of 375 mg/ m2 |
CYC + CS | 49 | 24 (49) | NA | NA | NA | 24 (49) | NA | ||||
Hussain [19] | 2022 | RTX | 25 | 10 (24) | 4 (17) | NA | NA | NA | NA | None | NA |
CYC | 25 | 19 (57) | 5 (20) | NA | NA | NA | NA | NA | |||
Zhou [20] | 2022 | RTX | 16 | 10 (62.5) | NA | NA | NA | NA | NA | None | RTX 1 g |
CYC + CS | 20 | 16 (80) | NA | NA | NA | NA | NA |